JP2018525430A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018525430A5 JP2018525430A5 JP2018511057A JP2018511057A JP2018525430A5 JP 2018525430 A5 JP2018525430 A5 JP 2018525430A5 JP 2018511057 A JP2018511057 A JP 2018511057A JP 2018511057 A JP2018511057 A JP 2018511057A JP 2018525430 A5 JP2018525430 A5 JP 2018525430A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- nhr
- group
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 60
- 125000003107 substituted aryl group Chemical group 0.000 claims 44
- 229910052757 nitrogen Inorganic materials 0.000 claims 32
- 125000001424 substituent group Chemical group 0.000 claims 31
- 125000003118 aryl group Chemical group 0.000 claims 30
- 125000001072 heteroaryl group Chemical group 0.000 claims 29
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 125000004122 cyclic group Chemical group 0.000 claims 21
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 16
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 16
- 150000001204 N-oxides Chemical class 0.000 claims 15
- 125000004432 carbon atom Chemical group C* 0.000 claims 15
- 229910052717 sulfur Inorganic materials 0.000 claims 15
- 125000005842 heteroatom Chemical group 0.000 claims 14
- 125000005843 halogen group Chemical group 0.000 claims 13
- 229910052760 oxygen Inorganic materials 0.000 claims 13
- 229910052736 halogen Inorganic materials 0.000 claims 11
- 150000002367 halogens Chemical class 0.000 claims 11
- 125000002883 imidazolyl group Chemical group 0.000 claims 10
- 125000002757 morpholinyl group Chemical group 0.000 claims 10
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 10
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 8
- -1 C 3-7 cyclic alkyl Chemical group 0.000 claims 8
- 125000003282 alkyl amino group Chemical group 0.000 claims 8
- 125000003725 azepanyl group Chemical group 0.000 claims 8
- 125000006165 cyclic alkyl group Chemical group 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 8
- 125000004193 piperazinyl group Chemical group 0.000 claims 8
- 125000003386 piperidinyl group Chemical group 0.000 claims 8
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 8
- 101100516554 Caenorhabditis elegans nhr-5 gene Proteins 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 125000000304 alkynyl group Chemical group 0.000 claims 6
- 125000002393 azetidinyl group Chemical group 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 101100516568 Caenorhabditis elegans nhr-7 gene Proteins 0.000 claims 4
- 101100516572 Caenorhabditis elegans nhr-8 gene Proteins 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 229920006395 saturated elastomer Polymers 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
- 101100240519 Caenorhabditis elegans nhr-13 gene Proteins 0.000 claims 2
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 claims 2
- 101710120843 Indoleamine 2,3-dioxygenase 1 Proteins 0.000 claims 2
- 101710136122 Tryptophan 2,3-dioxygenase Proteins 0.000 claims 2
- 102000057288 Tryptophan 2,3-dioxygenases Human genes 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- ONXJSWCJGQDQRB-UHFFFAOYSA-N 1-(5-chloro-4,6-dimethyl-[1,2]oxazolo[5,4-b]pyridin-3-yl)-3-(2-chlorophenyl)urea Chemical compound CC1=C(Cl)C(C)=C2C(NC(=O)NC3=C(Cl)C=CC=C3)=NOC2=N1 ONXJSWCJGQDQRB-UHFFFAOYSA-N 0.000 claims 1
- GUVHHBAQYNDOQA-UHFFFAOYSA-N 1-(5-chloro-4,6-dimethyl-[1,2]oxazolo[5,4-b]pyridin-3-yl)-3-(2-methoxyphenyl)urea Chemical compound COC1=C(NC(=O)NC2=NOC3=NC(C)=C(Cl)C(C)=C23)C=CC=C1 GUVHHBAQYNDOQA-UHFFFAOYSA-N 0.000 claims 1
- ZKPMHNKZZRXJEU-UHFFFAOYSA-N 1-(5-chloro-4,6-dimethyl-[1,2]oxazolo[5,4-b]pyridin-3-yl)-3-(3-chlorophenyl)urea Chemical compound CC1=C(Cl)C(C)=C2C(NC(=O)NC3=CC(Cl)=CC=C3)=NOC2=N1 ZKPMHNKZZRXJEU-UHFFFAOYSA-N 0.000 claims 1
- HTHMACSUVRONRQ-UHFFFAOYSA-N 1-(5-chloro-4,6-dimethyl-[1,2]oxazolo[5,4-b]pyridin-3-yl)-3-(3-methoxyphenyl)urea Chemical compound ClC=1C(=C2C(=NC=1C)ON=C2NC(=O)NC1=CC(=CC=C1)OC)C HTHMACSUVRONRQ-UHFFFAOYSA-N 0.000 claims 1
- OYTMNZZKMAODFF-UHFFFAOYSA-N 1-(5-chloro-4,6-dimethyl-[1,2]oxazolo[5,4-b]pyridin-3-yl)-3-(4-chlorophenyl)urea Chemical compound CC1=C(Cl)C(C)=C2C(NC(=O)NC3=CC=C(Cl)C=C3)=NOC2=N1 OYTMNZZKMAODFF-UHFFFAOYSA-N 0.000 claims 1
- LLIPTOCUBJBVQM-UHFFFAOYSA-N 1-(5-chloro-4,6-dimethyl-[1,2]oxazolo[5,4-b]pyridin-3-yl)-3-(4-cyanophenyl)urea Chemical compound CC1=C(Cl)C(C)=C2C(NC(=O)NC3=CC=C(C=C3)C#N)=NOC2=N1 LLIPTOCUBJBVQM-UHFFFAOYSA-N 0.000 claims 1
- KXVLEJZIDZJGTN-UHFFFAOYSA-N 1-(5-chloro-4,6-dimethyl-[1,2]oxazolo[5,4-b]pyridin-3-yl)-3-(4-methoxyphenyl)urea Chemical compound ClC=1C(=C2C(=NC=1C)ON=C2NC(=O)NC1=CC=C(C=C1)OC)C KXVLEJZIDZJGTN-UHFFFAOYSA-N 0.000 claims 1
- LJPBPWSBAAEXGB-UHFFFAOYSA-N 1-(5-chloro-4,6-dimethyl-[1,2]oxazolo[5,4-b]pyridin-3-yl)-3-[2-(trifluoromethoxy)phenyl]urea Chemical compound ClC=1C(=C2C(=NC=1C)ON=C2NC(=O)NC1=C(C=CC=C1)OC(F)(F)F)C LJPBPWSBAAEXGB-UHFFFAOYSA-N 0.000 claims 1
- YTGNWVMCEAAABQ-UHFFFAOYSA-N 1-(5-chloro-4,6-dimethyl-[1,2]oxazolo[5,4-b]pyridin-3-yl)-3-[2-(trifluoromethyl)phenyl]urea Chemical compound ClC=1C(=C2C(=NC=1C)ON=C2NC(=O)NC1=C(C=CC=C1)C(F)(F)F)C YTGNWVMCEAAABQ-UHFFFAOYSA-N 0.000 claims 1
- XLOUIZLWOJHUTJ-UHFFFAOYSA-N 1-(5-chloro-4,6-dimethyl-[1,2]oxazolo[5,4-b]pyridin-3-yl)-3-[3-(trifluoromethoxy)phenyl]urea Chemical compound ClC=1C(=C2C(=NC=1C)ON=C2NC(=O)NC1=CC(=CC=C1)OC(F)(F)F)C XLOUIZLWOJHUTJ-UHFFFAOYSA-N 0.000 claims 1
- NTNKYXWAKJZYDN-UHFFFAOYSA-N 1-(5-chloro-4,6-dimethyl-[1,2]oxazolo[5,4-b]pyridin-3-yl)-3-[3-(trifluoromethyl)phenyl]urea Chemical compound ClC=1C(=C2C(=NC=1C)ON=C2NC(=O)NC1=CC(=CC=C1)C(F)(F)F)C NTNKYXWAKJZYDN-UHFFFAOYSA-N 0.000 claims 1
- MKMUEPQDBRDIPR-UHFFFAOYSA-N 1-(5-chloro-4,6-dimethyl-[1,2]oxazolo[5,4-b]pyridin-3-yl)-3-[4-(trifluoromethoxy)phenyl]urea Chemical compound CC1=C(Cl)C(C)=C2C(NC(=O)NC3=CC=C(OC(F)(F)F)C=C3)=NOC2=N1 MKMUEPQDBRDIPR-UHFFFAOYSA-N 0.000 claims 1
- VVWRXPJEKFZHMF-UHFFFAOYSA-N 1-(5-chloro-4,6-dimethyl-[1,2]oxazolo[5,4-b]pyridin-3-yl)-3-[4-(trifluoromethyl)phenyl]urea Chemical compound CC1=C(Cl)C(C)=C2C(NC(=O)NC3=CC=C(C=C3)C(F)(F)F)=NOC2=N1 VVWRXPJEKFZHMF-UHFFFAOYSA-N 0.000 claims 1
- OCTHIRRMTADGPR-UHFFFAOYSA-N 1-(5-chloro-4,6-dimethyl-[1,2]oxazolo[5,4-b]pyridin-3-yl)-3-phenylurea Chemical compound ClC=1C(=C2C(=NC=1C)ON=C2NC(=O)NC1=CC=CC=C1)C OCTHIRRMTADGPR-UHFFFAOYSA-N 0.000 claims 1
- 206010002091 Anaesthesia Diseases 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- LQPAECYCNSYMPR-UHFFFAOYSA-N N-(5-chloro-4,6-dimethyl-[1,2]oxazolo[5,4-b]pyridin-3-yl)-2-phenylacetamide Chemical compound CC1=C(Cl)C(C)=C2C(NC(=O)CC3=CC=CC=C3)=NOC2=N1 LQPAECYCNSYMPR-UHFFFAOYSA-N 0.000 claims 1
- XOYBTIIRRPALOP-UHFFFAOYSA-N N-(5-chloro-4,6-dimethyl-[1,2]oxazolo[5,4-b]pyridin-3-yl)acetamide Chemical compound ClC=1C(=C2C(=NC=1C)ON=C2NC(C)=O)C XOYBTIIRRPALOP-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 230000037005 anaesthesia Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000004996 female reproductive system Anatomy 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- MPAJLQMQYTTZSB-UHFFFAOYSA-N n-[6-phenyl-4-(trifluoromethyl)-[1,2]oxazolo[5,4-b]pyridin-3-yl]cyclopropanecarboxamide Chemical compound C1=2C(C(F)(F)F)=CC(C=3C=CC=CC=3)=NC=2ON=C1NC(=O)C1CC1 MPAJLQMQYTTZSB-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021182007A JP2022033753A (ja) | 2015-08-27 | 2021-11-08 | トリプトファンジオキシゲナーゼ（ｉｄｏ１及びｔｄｏ）の阻害剤及び治療におけるその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ71151415 | 2015-08-27 | ||
| NZ711514 | 2015-08-27 | ||
| PCT/NZ2016/050135 WO2017034420A1 (en) | 2015-08-27 | 2016-08-25 | Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021182007A Division JP2022033753A (ja) | 2015-08-27 | 2021-11-08 | トリプトファンジオキシゲナーゼ（ｉｄｏ１及びｔｄｏ）の阻害剤及び治療におけるその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018525430A JP2018525430A (ja) | 2018-09-06 |
| JP2018525430A5 true JP2018525430A5 (enExample) | 2019-10-10 |
| JP7334041B2 JP7334041B2 (ja) | 2023-08-28 |
Family
ID=58100623
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018511057A Active JP7334041B2 (ja) | 2015-08-27 | 2016-08-25 | トリプトファンジオキシゲナーゼ（ｉｄｏ１及びｔｄｏ）の阻害剤及び治療におけるその使用 |
| JP2021182007A Pending JP2022033753A (ja) | 2015-08-27 | 2021-11-08 | トリプトファンジオキシゲナーゼ（ｉｄｏ１及びｔｄｏ）の阻害剤及び治療におけるその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021182007A Pending JP2022033753A (ja) | 2015-08-27 | 2021-11-08 | トリプトファンジオキシゲナーゼ（ｉｄｏ１及びｔｄｏ）の阻害剤及び治療におけるその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11414428B2 (enExample) |
| EP (1) | EP3350188B1 (enExample) |
| JP (2) | JP7334041B2 (enExample) |
| KR (1) | KR20180048798A (enExample) |
| CN (1) | CN108349997B (enExample) |
| AU (2) | AU2016312848A1 (enExample) |
| CA (1) | CA2996681C (enExample) |
| WO (1) | WO2017034420A1 (enExample) |
| ZA (1) | ZA201800787B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108349997B (zh) * | 2015-08-27 | 2025-06-10 | 奥克兰联合服务有限公司 | 色氨酸双加氧酶（ido1和tdo）抑制剂及其在治疗中的用途 |
| CN108969522B (zh) | 2017-06-05 | 2023-03-28 | 复旦大学 | N-苄基色胺酮类衍生物作为色氨酸双加氧酶(tdo)抑制剂的用途 |
| GB201809050D0 (en) | 2018-06-01 | 2018-07-18 | E Therapeutics Plc | Modulators of tryptophan catabolism |
| JP7566731B2 (ja) | 2018-07-03 | 2024-10-15 | アイエフエム デュー インコーポレイテッド | Ｓｔｉｎｇ活性に関連する状態を治療するための化合物および組成物 |
| US12152018B2 (en) | 2021-01-08 | 2024-11-26 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with STING activity |
| US20240091202A1 (en) | 2021-03-05 | 2024-03-21 | Universität Basel | Compositions for the treatment of ebv associated diseases or conditions |
| EP4052705A1 (en) | 2021-03-05 | 2022-09-07 | Universität Basel Vizerektorat Forschung | Compositions for the treatment of ebv associated diseases or conditions |
| WO2023166492A2 (en) | 2022-03-04 | 2023-09-07 | Antido Therapeutics International Sàrl | Dual inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001079193A2 (en) | 2000-04-14 | 2001-10-25 | Corvas International, Inc. | Substituted hydrazinyl heteroaromatic inhibitors of thrombin |
| WO2005089753A2 (en) * | 2004-03-16 | 2005-09-29 | Janssen Pharmaceutica N.V. | Daao inhibiting bξnzisoxazoles and their use for the treatment of mental disorders |
| TW200633990A (en) * | 2004-11-18 | 2006-10-01 | Takeda Pharmaceuticals Co | Amide compound |
| DE102005018389A1 (de) | 2005-04-20 | 2006-10-26 | Sanofi-Aventis Deutschland Gmbh | Azolderivate als Inhibitoren von Lipasen und Phospholipasen |
| DE102005038947A1 (de) | 2005-05-18 | 2006-11-30 | Grünenthal GmbH | Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln |
| DE102005026194A1 (de) * | 2005-06-06 | 2006-12-07 | Grünenthal GmbH | Substituierte N-Benzo[d]isoxazol-3-yl-amin-Derivate und deren Verwendung zur Herstellung von Arzneimitteln |
| CA2932121A1 (en) | 2007-11-30 | 2009-06-11 | Newlink Genetics Corporation | Ido inhibitors |
| US8461159B2 (en) | 2008-11-25 | 2013-06-11 | Jannsen Pharmaceutica BV | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
| WO2010068452A1 (en) * | 2008-11-25 | 2010-06-17 | Janssen Pharmaceutica Nv | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
| CA2754934A1 (en) | 2009-03-10 | 2010-09-16 | Gruenenthal Gmbh | Substituted 3-aminoisoxazolopyridines as kcnq2/3 modulators |
| JP2013519685A (ja) | 2010-02-11 | 2013-05-30 | ヴァンダービルト ユニバーシティー | ｍＧｌｕＲ４アロステリック増強剤としてのベンズイソオキサゾール類およびアザベンズイソオキサゾール類、組成物、および神経機能不全を治療する方法 |
| JP6039554B2 (ja) | 2010-07-22 | 2016-12-07 | ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ | 除草性イソオキサゾロ［５，４−ｂ］ピリジン |
| EP2802212B1 (en) | 2012-01-12 | 2015-12-30 | Basf Se | Herbicidal isoxazolo[5,4-b]pyridines |
| PL220630B1 (pl) | 2012-12-28 | 2015-11-30 | Inst Immunologii I Terapii Doświadczalnej Pan | Nowe sulfonamidowe pochodne izoksazolo[5,4-b]pirydyny o aktywności przeciwbakteryjnej, sposób ich wytwarzania oraz nowe zastosowanie 3-aminoizoksazolo[5,4-b]pirydyny |
| EA201591610A1 (ru) * | 2013-03-14 | 2015-12-30 | Курадев Фарма Прайвит Лтд. | Ингибиторы кинуренинового пути |
| WO2015082499A2 (en) | 2013-12-03 | 2015-06-11 | Iomet Pharma Ltd | Pharmaceutical compound |
| JP7323985B2 (ja) | 2014-08-13 | 2023-08-09 | オークランド ユニサービシーズ リミティド | トリプトファンジオキシゲナーゼ（ｉｄｏ１とｔｄｏ）の阻害剤及び治療におけるその使用 |
| CN108349997B (zh) * | 2015-08-27 | 2025-06-10 | 奥克兰联合服务有限公司 | 色氨酸双加氧酶（ido1和tdo）抑制剂及其在治疗中的用途 |
| RU2619120C1 (ru) | 2016-06-06 | 2017-05-12 | Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кубанский государственный аграрный университет" | 5-Хлор-3-(3-хлорфенилкарбоксамидо)-4,6-диметилизоксазоло[5,4-b]пиридин в качестве антидота 2,4-Д на подсолнечнике |
-
2016
- 2016-08-25 CN CN201680063267.2A patent/CN108349997B/zh active Active
- 2016-08-25 US US15/755,750 patent/US11414428B2/en active Active
- 2016-08-25 AU AU2016312848A patent/AU2016312848A1/en not_active Abandoned
- 2016-08-25 EP EP16839685.1A patent/EP3350188B1/en active Active
- 2016-08-25 JP JP2018511057A patent/JP7334041B2/ja active Active
- 2016-08-25 CA CA2996681A patent/CA2996681C/en active Active
- 2016-08-25 WO PCT/NZ2016/050135 patent/WO2017034420A1/en not_active Ceased
- 2016-08-25 KR KR1020187008532A patent/KR20180048798A/ko not_active Withdrawn
-
2018
- 2018-02-06 ZA ZA2018/00787A patent/ZA201800787B/en unknown
-
2021
- 2021-08-03 AU AU2021212003A patent/AU2021212003B2/en active Active
- 2021-11-08 JP JP2021182007A patent/JP2022033753A/ja active Pending
-
2022
- 2022-08-15 US US17/888,281 patent/US20220411438A1/en not_active Abandoned